Access to medications is a vital aspect of maintaining healthy lives, and the urge to invest in personal health has only grown since the COVID-19 pandemic.
The COVID-19 pandemic has highlighted the importance of ensuring a reliable supply of treatments across the globe at pace and speed. Jirair Ratevosian, executive director of global patient
Our growing understanding of human biology is accelerating medical science at an unprecedented rate – but more needs to be done to ensure everyone can get access to medication they need.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh